|
Acute Kidney Injury May Be More Deadly Than Heart Attacks
Science Daily (press release) Dec. 5, 2013 — Acute kidney injury, a condition that is common but often asymptomatic, may be more deadly than a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). |
Obinutuzumab Tops Rituximab in CLL Trial – Cancer Network
This is Local London |
Obinutuzumab Tops Rituximab in CLL Trial
Cancer Network Obinutuzumab topped rituximab in a large chronic lymphocytic leukemia (CLL) trial of older, newly diagnosed patients, demonstrating improvements in response rate and progression-free survival (PFS), according to results presented at the 2013 American … Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patientsThe Oncology Report Dr. Goede on Obinutuzumab Versus Rituximab in CLLOncLive New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Healio –PR Newswire (press release) all 16 news articles » |
Covagen gets up to $63M in VC round for multitargeted antibodies – FierceBiotech
Covagen gets up to $63M in VC round for multitargeted antibodiesFierceBiotechResearchers at Swiss biotech startup Covagen are in the business of building multitargeted antibodies, new bi- and trispecific therapies which are created by fusing short prot…
The Year in Rheumatology: 2013 – Medscape
MedscapeThe Year in Rheumatology: 2013MedscapeNonclinical assessments demonstrating the similarity of the proposed biosimilar PF-05280586 and rituximab. Program and abstracts of the European League Against Rheumatism (EULAR) Congress 2013; June 12-15, …
Organ donation: Beauty that comes from a tragedy – Kelowna Capital News
|
Organ donation: Beauty that comes from a tragedy
Kelowna Capital News Dulce Intengan had one question nobody could answer in the days before her husband’s heart was stopped. “I asked the doctor, ‘Will he still love me the same after the transplant?’” Intengan said, Wednesday as she, her husband and several others … Organ recipients thank Comox hospital for transplantsComox Vallety Record |
Fake blood donation shames Congress in Andhra Pradesh – Deccan Chronicle
Fake blood donation shames Congress in Andhra PradeshDeccan ChronicleHyderabad: Plumbing new depths of sycophancy, dozens of Mahila Congress activists happily posed for photographs claiming that they had donated blood to mark the birthday of party pres…
Shark Antibodies May Cure Breast Cancer and Aid Survival of the Fittest – Guardian Express
Guardian Express |
Shark Antibodies May Cure Breast Cancer and Aid Survival of the Fittest
Guardian Express Studies have suggested that shark antibodies may help cure breast cancer, and in effect aid Darwin’s theory of survival of the fittest within humanity, like they do in oceanic ecosystems. Sharks are extremely crucial oceanic fish. They are … |
Kids' Liver Transplant Success Varies by Race, Research Shows – HealthDay
|
Kids’ Liver Transplant Success Varies by Race, Research Shows
HealthDay “Further investigation of the reasons for racial and ethnic differences, particularly on a national level, is necessary to identify interventions that may help reduce disparities in pediatric liver transplantation,” she concluded. Over the past 30 … |
Results Presented for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma – Monthly Prescribing Reference
|
Results Presented for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Monthly Prescribing Reference Gilead announced results from the Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to … Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent …Business Wire (press release) Gilead Announces Pivotal Phase 2 Results For Idelalisib In Refractory iNHLRTT News |
ImmunoGen, Inc. : Announces Activity Reported with SAR3419 Plus Rituxan In … – 4-traders (press release)
|
ImmunoGen, Inc. : Announces Activity Reported with SAR3419 Plus Rituxan In …
4-traders (press release) … technology, today announced the presentation of clinical findings with SAR3419 (coltuximab ravtansine) used in combination with Rituxan® (rituximab) to treat diffuse large B-cell lymphoma (DLBCL) that previously had been treated with standard … |